Bussiness5 months ago
Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
Vaxcyte, Inc. — VAX-31 Adult Phase 1/2 Study Topline Safety, Tolerability and Immunogenicity Data Expected in September 2024 — — Following VAX-31 Adult Phase 1/2 Study...
